Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akari Therapeutics PlcAKTX · Entity 7692 | Director · 10% owner | December 16, 2025 | December 18, 2025 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 13, 2018 | June 15, 2018 |
| Eidos Therapeutics, Inc.EIDX · Entity 143355 | Director | June 22, 2018 | June 22, 2018 |
| GERON CORPGERN · Entity 4989 | Director | May 15, 2018 | May 17, 2018 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 11, 2026 | June 12, 2026 |
| Peak Bio, Inc.PKBO · Entity 85431 | Director · 10% owner | November 14, 2024 | November 18, 2024 |
| Rezolute, Inc.ANTB · Entity 1990 | Director · Chairman, Scientific Adv. Bd. | October 31, 2016 | January 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akari Therapeutics Plc
Report date December 16, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants to purchase American Depositary Shares ("ADRs")SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 | Direct | 618,658 |
Reported balance
After 2025-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-16 · Purchase · Acquired 618,658 · Balance 618,658 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. |
| Pre-Funded Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 618,658 |
Reported balance
After 2025-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-16 · Purchase · Acquired 618,658 · Balance 618,658 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F7: Conversion Exercise Price of Security is $0.00001 F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. |
| Pre-Funded Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,093,293 |
Reported balance
After 2025-12-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-16 · Purchase · Acquired 3,093,293 · Balance 3,093,293 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the "Note Exchange Unregistered Warrants"). F7: Conversion Exercise Price of Security is $0.00001 F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. |
| Warrants to purchase ADRsSEC Table II · derivative / convertible security · Conversion / exercise price $0.39 | Direct | 3,093,293 |
Reported balance
After 2025-12-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-16 · Purchase · Acquired 3,093,293 · Balance 3,093,293 F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the "Note Exchange Unregistered Warrants"). F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.
F2: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.
F3: The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.
F4: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.
F5: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the "Note Exchange Unregistered Warrants").
F6: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.
F7: Conversion Exercise Price of Security is $0.00001
CytomX Therapeutics, Inc.
Report date June 13, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.25 · Expires 2028-06-12 | Direct | 14,000 |
Reported balance
After 2018-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-13 · Grant · Acquired 14,000 · Balance 14,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Eidos Therapeutics, Inc.
Report date June 22, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2028-06-21 | Direct | 83,750 |
Reported balance
After 2018-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-22 · Grant · Acquired 83,720 · Balance 83,750 F1: The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 83,720 stock options (the "Grant") on June 22, 2018 (the "Grant Date"). The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following the Grant Date subject to the Reporting Person's continued service to the Issuer through each vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 83,720 stock options (the "Grant") on June 22, 2018 (the "Grant Date"). The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following the Grant Date subject to the Reporting Person's continued service to the Issuer through each vesting date
GERON CORP
Report date May 15, 2018 · Filed May 17, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2028-05-14 | Direct | 70,000 |
Reported balance
After 2018-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-15 · Grant · Acquired 70,000 · Balance 70,000 F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates.
PLIANT THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2036-06-11 | Direct | 70,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 70,000 · Balance 70,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Peak Bio, Inc.
Report date November 14, 2024 · Filed November 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,574,661 |
Reported balance
After 2024-11-14 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-11-14 · Conversion · Acquired 4,574,661 · Balance 4,574,661 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F2: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-11-14 · Disposition to issuer · Disposed 4,574,661 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2024-11-14 · Disposition to issuer · Disposed 8,382,742 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-11-14 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2024-11-14 · Disposition to issuer · Disposed 372,940 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent. F4: The securities are held by Hannol Ventures LLC. The Reporting Person is sole member of the LLC. |
| Convertible NotesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-11-14 · Conversion · Disposed Not disclosed · Balance 0 F2: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock"). F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). |
| Warrant (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-11-14 · Disposition to issuer · Disposed 176,292 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a "Peak Warrant") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the "Assumed Warrants"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-11-14 · Disposition to issuer · Disposed 1,200,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F6: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").
F2: Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock").
F3: At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent.
F4: The securities are held by Hannol Ventures LLC. The Reporting Person is sole member of the LLC.
F5: At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a "Peak Warrant") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the "Assumed Warrants"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio.
F6: At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio.
Rezolute, Inc.
Report date October 31, 2016 · Filed January 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2026-10-31 | Direct | 4,000,000 |
Reported balance
After 2016-10-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-10-31 · Grant · Acquired 4,000,000 · Balance 4,000,000 F1: On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria. F2: The option vests in forty-eight equal installments beginning on the date so indicated and every month thereafter, such grant vested in full at 4 years. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria.
F2: The option vests in forty-eight equal installments beginning on the date so indicated and every month thereafter, such grant vested in full at 4 years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2022 Filed Nov 3, 2022 21:50 UTC | Peak Bio, Inc. PKBO · Entity 85431 | OtherCommon Stock | 372,562 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035081 · doc4.xml · nonDerivative · entry 2 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 372,652 F1 · price: Received pursuant to the consummation of the transactions contemplated by that certain Business Combination Agreement between Ignyte Acquisition Corp. (the former name of the Issuer), a Delaware corporation, Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea, and Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic of Korea. F2 · ownership.nature: The securities are held by Hannol Ventures LLC (the "LLC"). The Reporting Person is sole member of the LLC. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:50 UTC | Peak Bio, Inc. PKBO · Entity 85431 | OtherCommon Stock | 6,442,438 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035081 · doc4.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,422,438 F1 · price: Received pursuant to the consummation of the transactions contemplated by that certain Business Combination Agreement between Ignyte Acquisition Corp. (the former name of the Issuer), a Delaware corporation, Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea, and Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic of Korea. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 16:21 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001567619-22-013199 · doc1.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters beginning October 1st and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 16, 2022 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:47 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 13,286 | $0.00 Strike: $28.20 | $0.00 |
DisclosureSEC source: 0001209191-21-044178 · doc4.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,286 Underlying: Common Stock · 13,286 shares Expires 2031-06-28 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 21:21 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | ConversionSeries A Preferred Stock · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015879 · doc4.xml · derivative · entry 2 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 139,860 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by pH Pharma Co., Ltd. ("pH Pharma"). The Reporting Person has a majority ownership in pH Pharma and also has voting power over the shares. The Reporting Person disclaims beneficial ownership of the shares held by pH Pharma, except to the extent of his proportionate pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 21:21 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | ConversionCommon Stock | 139,860 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-015879 · doc4.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 239,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by pH Pharma Co., Ltd. ("pH Pharma"). The Reporting Person has a majority ownership in pH Pharma and also has voting power over the shares. The Reporting Person disclaims beneficial ownership of the shares held by pH Pharma, except to the extent of his proportionate pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 22, 2018 Filed Jun 22, 2018 18:55 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantStock Option (right to buy) · Derivative | 83,720 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017777 · doc4.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,750 Underlying: Common Stock · 83,720 shares Expires 2028-06-21 F1 · derivative.exercise_date: The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 83,720 stock options (the "Grant") on June 22, 2018 (the "Grant Date"). The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following the Grant Date subject to the Reporting Person's continued service to the Issuer through each vesting date Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 17:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0000899243-18-016823 · doc4.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:42 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000886744-18-000033 · edgar.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-05-14 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:13 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 10,764 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-18-000001 · edgar.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,301 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 21:25 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 8,888 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-17-000041 · edgar.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,537 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 29, 2017 of $2.18 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 29, 2017 of $2.18 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 29, 2017 of $2.18 per share. Read SEC document |
| June 30, 2017 Filed Jun 30, 2017 23:44 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 6,995 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-17-000035 · edgar.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,649 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 30, 2017 of $2.77 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 30, 2017 of $2.77 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 30, 2017 of $2.77 per share. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 13:58 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0001140361-17-025790 · doc1.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The option vests in full on June 20, 2018 subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| May 09, 2017 Filed May 11, 2017 00:51 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000886744-17-000028 · edgar.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates. Read SEC document |
| March 31, 2017 Filed Mar 31, 2017 23:35 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 8,535 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-17-000018 · edgar.xml · nonDerivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,654 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 31, 2017 of $2.27 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 31, 2017 of $2.27 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 31, 2017 of $2.27 per share. Read SEC document |
| October 31, 2016 Filed Jan 18, 2017 15:28 UTC | Rezolute, Inc. ANTB · Entity 1990 | GrantStock Option (right to buy) · Derivative | 4,000,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001140361-17-002117 · doc1.xml · derivative · entry 1 Huh Hoyoung · CIK 0001401267 · Director · Chairman, Scientific Adv. Bd. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000,000 Underlying: Common Stock · 4,000,000 shares Expires 2026-10-31 F1 · shares: On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria. F2 · derivative.exercise_date: The option vests in forty-eight equal installments beginning on the date so indicated and every month thereafter, such grant vested in full at 4 years. F1 · derivative.underlying_shares: On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria. F1 · balance_after: On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.